PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ETRASIMOD (APD334) IN SUBJECTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT: A SINGLE-DOSE, OPEN-LABEL, PARALLEL-GROUP STUDY
Caroline A. Lee 1
Yong Tang 1
Cassandra Schroeder 1
Jinkun Zhang 1
Thai Nguyen-Cleary 1
Susan Mullin 1
Michael Ma 1
Naomi Lyon 1
John S. Grundy 1
1 Arena Pharmaceuticals, Inc., San Diego, United States
Session
IBD (Posters)
Conference
UEG Week Virtual 2021
Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]